ecancermedicalscience

Case Report

Pegylated Liposomal Doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo

9 Dec 2008
Y Yuan, SJ Orlow, J Curtin, A Downey, F Muggia

Pegylated liposomal doxorubicin (PLD, Doxil, Caelyx) is widely used for the treatment of ovarian cancer. It is a stable formulation encapsulating doxorubicin in a ‘Stealth’ (i.e., pegylated) liposome with a half-life of about 72 hours. This drastically altered pharmacology confers on it a considerably lower risk of cardiotoxicity, no acute emesis, and near absence of alopecia or problems with extravasation necrosis. On the other hand, PLD's dose-limiting toxicity is cutaneous. Since the original phase I report, cutaneous toxicities reported with PLD fall into four common categories: the well known hand-foot syndrome (also called palmoplantar erythrodysesthesia, or PPE), a diffuse follicular rash, intertrigo-like eruption, and hyperpigmentation including melanotic macules.

Article metrics: 2476 views
917
1559

Related Articles

Maria Gosein, Laura Mohammed, Adrian Chan, Alexander Sinanan, Renee Banfield, Paramanand Maharaj, Dylan Narinesingh
Maria Asunción Algarra, Maria José Juan Fita, Sergio Sandiego, Héctor Augusto Aguilar, Pablo Álvarez, Mateo Quispe, Antonio Salvador, Adoración Egido, Javier Lavernia, Isidro Machado, José Rubio Briones, Miguel Ángel Climent
Lekha Madhavan Nair, KM Jagathnath Krishna, Aswin Kumar, Susan Mathews, John Joseph, Francis Vadakkumparambil James